Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06655051

Single Plastic Stent Vs. Fully Covered Self-Expanding Metal Stent on Benign Biliary Stricture Secondary to Chronic Pancreatitis

The goal of this clinical trial is to compare the efficacy and safety of a single plastic stent versus a fully covered self-expanded metal stent in relieving benign biliary stricture secondary to chronic pancreatitis. The main questions it aims to answer is:

Whether the efficacy of a single plastic stent is non-inferior to that of a fully covered metal stent in patients with benign biliary stricture secondary to chronic pancreatitis?

Participants will be randomly assigned to receive either a single plastic stent (SPS) placement or fully covered self-expanded metal stent placement treatment for 6 months, and they will be followed up for 18 months.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Shanghai Changhai Hospital Clinical Research Ward

Shanghai, Shanghai Municipality, 200433, China

Location status: Recruiting

Location contact

Lianghao Hu, M.D.

CONTACT

[email protected]

About this study

Although a number of previous studies have shown that the drainage and dilation effect of a single plastic stent is limited for benign biliary stricture (BBS) secondary to chronic pancreatitis (CP), the poor management of CP itself in most studies may explain the unsatisfactory efficacy of a single biliary plastic stent in relieving CP secondary BBS. Investigators believe that the effective management of CP is an important step to solve the BBS secondary to CP, especially the effective removal of pancreatic duct stones, the relief of pancreatic duct obstruction and the maintenance of pancreatic duct patency. Previous data showed that in CP patients treated with ESWL combined with ERCP, 72.4% could achieve complete removal of main pancreatic duct stones and 90.8% could achieve successful endoscopic decompression. Under the premise of effectively removing the stones of the main pancreatic duct at the head of the pancreas and maintaining the patency of the pancreatic duct, using a single plastic stent for stent drainage of BBS is effective, and a single plastic stent has potential advantages such as lower stent displacement rate and cheaper. Therefore, investigators design a single-center, prospective, open-label, randomized controlled, non-inferiority trial to compare the effectiveness, safety, and cost-effectiveness of a single plastic stent and fcSEMS for the removal of CP secondary BBS under the premise that the primary disease, i.e. CP itself, was effectively managed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 or older;
  • Patients diagnosed with CP;
  • Symptomatic biliary stricture documented at time of enrollment for naïve stricture or at the time of prior plastic stent placement in strictures that had 1 prior plastic stent inserted: cholangitis, and/or an increase in total bilirubin or alkaline phosphatase levels(> 2 times the upper limit of normal) for more than 4 weeks;
  • Confirmation of bile duct stricture by imaging assessment.

Exclusion criteria

  • Prior plastic stenting exceeding six months or any metal stenting;
  • Incomplete removal of stones from the main pancreatic duct located in the head of the pancreas during ERCP procedures;
  • Biliary stricture of benign etiology other than chronic pancreatitis;
  • Developing obstructive biliary symptoms associated with an attack of acute pancreatitis;
  • Stricture within 2 cm of common bile duct bifurcation;
  • Biliary stricture of malignant etiology;
  • Patients with acute or chronic hepatitis, cirrhosis, primary sclerosing cholangitis, congenital biliary malformations or biliary fistula;
  • Symptomatic duodenal stenosis (with gastric stasis);
  • Subjects for whom endoscopic techniques are contraindicated;
  • Pregnancy, incarceration;
  • Life expectancy < 1 year;
  • Other conditions that inappropriate to participant in the study.

Treatment and study plan

endoscopic retrograde biliary drainage (single plastic stent)

Device

Participants will undergo ERCP. A flexible tube is inserted into the duodenum, crossing the sphincter of Oddi to access the biliary system. And the location, diameter, and length of biliary stricture will be evaluated by injection of contrast media. A single plastic stent is then placed across the biliary stricture, allowing the bile duct to resume drainage. The participants will be observed closely after ERCP and record complications. Imaging evaluation will be conducted 6 months after stenting to confirm spontaneous passage of the biliary duct stent, and the stent will be removed via ERCP if it is still in place.

endoscopic retrograde biliary drainage ( fully covered self-expanding metal stent)

Device

Participants will undergo ERCP. A flexible tube is inserted into the duodenum, crossing the sphincter of Oddi to access the biliary system. And the location, diameter, and length of biliary stricture will be evaluated by injection of contrast media. A fully covered self-expanding metal stent is then placed across the biliary stricture, allowing the bile duct to resume drainage. The participants will be observed closely after ERCP and record complications. Imaging evaluation will be conducted 6 months after stenting to confirm spontaneous passage of the biliary duct stent, and the stent will be removed via ERCP if it is still in place.

Primary outcomes

  1. Long-term stricture resolution

    Time frame: 2 years after enrollment

    Stricture resolution assessed at the time of final stent removal as well as the absence of objective findings of stricture recurrence during the 18 months, post-stenting follow-up period.

Secondary outcomes

  1. Early clinical success

    Time frame: 6 months after enrollment

    Stricture resolution at the time all stent is removed. If there is a persistent stricture after 6 months of stent therapy in either group, the patient will be classified as a clinical failure.

  2. Technical success

    Time frame: 6 months after enrollment

    The completion of the initial and each follow-up ERCP, including stent deployment and removal.

  3. Adverse events related to the device or procedure

    Time frame: 2 years after enrollment

    Device or procedure related adverse events from the initial stent placement procedure to the 2 year follow-up.

  4. Length of stent placement and removal procedures

    Time frame: 6 months after enrollment

    Length of stent placement procedures and stent removal procedures.

  5. Number of ERCP procedures after Initial stent placement.

    Time frame: 6 months after enrollment

    The number of endoscopic retrograde cholangiopancreatography (ERCP) procedures after initial stent placement.

  6. Number of stents placed

    Time frame: 6 months after enrollment

    The total number of stents placed

Study contacts

Contact information is provided by the study sponsor or research team.

Lianghao Hu, M.D.

CONTACT

[email protected]

+86-13817593520

Zhaoshen Li, M.D.

CONTACT

[email protected]

+86-13901960921

Sponsors and collaborators

Lead sponsor

Changhai Hospital

Other

Registry information

Official study title

Efficacy and Safety of Single Plastic Stent Compared With Fully Covered Self-Expanding Metal Stent on Benign Biliary Stricture Secondary to Chronic Pancreatitis: A Single Center,Prospective,Non-inferiority, Open Label, Randomized, Controlled Trial

Acronym: ESSENCE

Important dates

Study start
2025
Primary completion
2030
Study completion
2030
First posted
Oct 23, 2024
Registry last updated
May 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.